Published in Vaccine on February 20, 2008
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol (2009) 2.79
Vaccine-induced myeloid cell population dampens protective immunity to SIV. J Clin Invest (2014) 1.64
Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A (2010) 1.37
Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J Immunol (2009) 1.18
Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS One (2010) 1.05
Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine (2009) 1.05
Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One (2010) 1.01
Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection. PLoS One (2012) 0.97
Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin Immunol (2010) 0.96
Optimizing NKT cell ligands as vaccine adjuvants. Immunotherapy (2014) 0.93
Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents. Clin Transl Immunology (2016) 0.88
DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells. Vaccine (2010) 0.88
NKT cell immune responses to viral infection. Expert Opin Ther Targets (2009) 0.88
Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet. Int J Mol Sci (2012) 0.87
A double-edged sword: the role of NKT cells in malaria and HIV infection and immunity. Semin Immunol (2009) 0.86
Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants. Expert Rev Vaccines (2008) 0.86
Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells. PLoS One (2014) 0.82
Invariant NKT cell response to dengue virus infection in human. PLoS Negl Trop Dis (2014) 0.81
Regulation of NKT Cell Localization in Homeostasis and Infection. Front Immunol (2015) 0.81
The Role of Invariant Natural Killer T Cells in Dendritic Cell Licensing, Cross-Priming, and Memory CD8(+) T Cell Generation. Front Immunol (2015) 0.80
Design, Synthesis, and Immunological Evaluation of Benzyloxyalkyl-Substituted 1,2,3-Triazolyl α-GalCer Analogues. ACS Med Chem Lett (2015) 0.78
Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvants. Front Biol (Beijing) (2012) 0.78
Glucosylceramide Administration as a Vaccination Strategy in Mouse Models of Cryptococcosis. PLoS One (2016) 0.78
Colocalization of a CD1d-Binding Glycolipid with a Radiation-Attenuated Sporozoite Vaccine in Lymph Node-Resident Dendritic Cells for a Robust Adjuvant Effect. J Immunol (2015) 0.77
Natural killer T cell based Immunotherapy. J Vaccines Vaccin (2012) 0.77
mTOR Regulation of Lymphoid Cells in Immunity to Pathogens. Front Immunol (2016) 0.77
In-vivo stimulation of macaque natural killer T cells with α-galactosylceramide. Clin Exp Immunol (2013) 0.77
Glycolipid activators of invariant NKT cells as vaccine adjuvants. Immunogenetics (2016) 0.76
Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine. J Biomed Sci (2016) 0.75
Novel galactosyl donor with 2-naphthylmethyl (NAP) as the non participating group at C-2 position: Efficient synthesis of alpha-galactosyl ceramide. Tetrahedron Lett (2010) 0.75
A potent adjuvant effect of a CD1d-binding NKT cell ligand in human immune system mice. Expert Rev Vaccines (2016) 0.75
Identification of microRNAs of the herpesvirus family. Nat Methods (2005) 12.98
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Recognition of bacterial glycosphingolipids by natural killer T cells. Nature (2005) 6.38
Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci U S A (2002) 6.00
Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol (2006) 5.51
Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood (2011) 4.35
Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet (2005) 4.21
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol (2003) 4.12
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature (2010) 3.96
Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog (2005) 3.59
Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol (2011) 3.48
The changing face of HIV in China. Nature (2008) 3.39
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res (2011) 3.05
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet (2006) 2.86
Retracted Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science (2002) 2.81
A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med (2011) 2.78
Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J Exp Med (2003) 2.64
Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med (2002) 2.38
Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS Med (2006) 2.37
Primary language and receipt of recommended health care among Hispanics in the United States. J Gen Intern Med (2007) 2.23
Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci U S A (2005) 2.13
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science (2014) 2.11
Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr (2004) 2.05
Efficacy of platelet-rich plasma combined with allograft bone in the management of displaced intra-articular calcaneal fractures: a prospective cohort study. J Orthop Res (2012) 2.04
A case series of 104 women infected with HIV-1 via blood transfusion postnatally: high rate of HIV-1 transmission to infants through breast-feeding. J Infect Dis (2009) 2.02
Experimental free energy surface reconstruction from single-molecule force spectroscopy using Jarzynski's equality. Phys Rev Lett (2007) 1.95
HIV-1 dynamics in vivo: implications for therapy. Nat Rev Microbiol (2003) 1.94
Trend and disease burden of bacillary dysentery in China (1991-2000). Bull World Health Organ (2006) 1.93
Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis (2003) 1.90
Turnover rates of B cells, T cells, and NK cells in simian immunodeficiency virus-infected and uninfected rhesus macaques. J Immunol (2003) 1.87
In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted? Proc Natl Acad Sci U S A (2002) 1.82
Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells. J Immunol (2009) 1.81
Research on an Mg-Zn alloy as a degradable biomaterial. Acta Biomater (2009) 1.80
Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc Natl Acad Sci U S A (2013) 1.76
Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol (2004) 1.76
Aerobic methane emission from plants in the Inner Mongolia steppe. Environ Sci Technol (2008) 1.76
Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci U S A (2006) 1.74
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One (2011) 1.71
Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virus. Eur J Immunol (2005) 1.60
Adenovirus-mediated small-interference RNA for in vivo silencing of angiotensin AT1a receptors in mouse brain. Hypertension (2005) 1.60
CO2 emissions from land-use change affected more by nitrogen cycle, than by the choice of land-cover data. Glob Chang Biol (2013) 1.59
A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A (2008) 1.59
Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci U S A (2003) 1.56
Developmental expression of solute carrier family 26A member 4 (SLC26A4/pendrin) during amelogenesis in developing rodent teeth. Eur J Oral Sci (2011) 1.55
Delayed build-up of Arctic ice sheets during 400,000-year minima in insolation variability. Nature (2012) 1.53
Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood (2002) 1.53
Exposure of R169 controls protein C activation and autoactivation. Blood (2012) 1.52
Viral blip dynamics during highly active antiretroviral therapy. J Virol (2003) 1.51
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol (2013) 1.50
Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc Natl Acad Sci U S A (2007) 1.48
High prevalence of HIV infection among women and their children in Henan Province, China. J Acquir Immune Defic Syndr (2003) 1.47
Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. J Am Chem Soc (2006) 1.47
Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis (2002) 1.45
Surface-based TBM boosts power to detect disease effects on the brain: an N=804 ADNI study. Neuroimage (2011) 1.41
Pressure-induced metallization of silane. Proc Natl Acad Sci U S A (2007) 1.39
Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A (2010) 1.37
Corneal power measurement with Fourier-domain optical coherence tomography. J Cataract Refract Surg (2010) 1.35
The C-glycoside analogue of the immunostimulant alpha-galactosylceramide (KRN7000): synthesis and striking enhancement of activity. Angew Chem Int Ed Engl (2004) 1.31
Structural identification of the pathway of long-range communication in an allosteric enzyme. Proc Natl Acad Sci U S A (2008) 1.31
Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc Natl Acad Sci U S A (2005) 1.29
Human genital epithelial cells capture cell-free human immunodeficiency virus type 1 and transmit the virus to CD4+ Cells: implications for mechanisms of sexual transmission. J Infect Dis (2003) 1.29
Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. J Clin Endocrinol Metab (2004) 1.29
Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts). Mod Pathol (2009) 1.29
Human immunodeficiency virus type 1 (HIV-1)-specific CD8+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes. J Virol (2002) 1.28
Quantification of fossil fuel CO2 emissions on the building/street scale for a large U.S. city. Environ Sci Technol (2012) 1.28
Structure-activity relationships for hydroxylated polychlorinated biphenyls as substrates and inhibitors of rat sulfotransferases and modification of these relationships by changes in thiol status. Drug Metab Dispos (2009) 1.27
Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses. J Immunol (2008) 1.26
Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. J Virol (2002) 1.25
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology (2013) 1.24
Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antivir Ther (2004) 1.23
Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4. Proc Natl Acad Sci U S A (2007) 1.23
Efficient synthesis of alpha-C-galactosyl ceramide immunostimulants: use of ethylene-promoted olefin cross-metathesis. Org Lett (2004) 1.19
Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res (2007) 1.19
Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J Virol (2010) 1.19
Intraoperative (125)I Vicryl mesh brachytherapy after sublobar resection for high-risk stage I non-small cell lung cancer. Brachytherapy (2005) 1.18
Immune status, antibiotic medication and pH are associated with changes in the stomach fluid microbiota. ISME J (2013) 1.17
Cognitive dysfunction in mice infected with Plasmodium berghei strain ANKA. J Infect Dis (2008) 1.16
HIV-1 subtype B' dictates the AIDS epidemic among paid blood donors in the Henan and Hubei provinces of China. AIDS (2003) 1.16
Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody. Structure (2010) 1.15
Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. Gerontology (2010) 1.14
Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math Biosci (2004) 1.14
Protein geometry and placement in the cardiac dyad influence macroscopic properties of calcium-induced calcium release. Biophys J (2007) 1.14
Identification of C-glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells. Immunology (2009) 1.12
Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest (2010) 1.12
Estimating average cellular turnover from 5-bromo-2'-deoxyuridine (BrdU) measurements. Proc Biol Sci (2003) 1.11
Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgrad Med J (2010) 1.11
Developmental delays consistent with cochlear hypothyroidism contribute to failure to develop hearing in mice lacking Slc26a4/pendrin expression. Am J Physiol Renal Physiol (2009) 1.10
Biochemical characterization and crystal structure of endoglucanase Cel5A from the hyperthermophilic Thermotoga maritima. J Struct Biol (2010) 1.10